Jan C. Brase
YOU?
Author Swipe
View article: A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer Open
PURPOSE: Predicting prognosis in HR+/HER2- metastatic breast cancer (MBC) might be clinically useful; however, no validated prognostic biomarkers exist in this setting to date. PATIENTS AND METHODS: In phase III, EGF3…
View article: Figure 4 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure 4 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
PFS by treatment in: (A) CD8 low and PD-L1 <1%; (B) CD8 low and PD-L1 ≥1%; (C) CD8 high and PD-L1 <1%; (D) CD8 high and PD-L1 ≥1%. OS by treatment in: (E) CD8 low and PD-L1 <1%; (F) CD8 low and PD-…
View article: Figure S1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
A, CANOPY-1 and B, CANOPY-N study designs.
View article: Figure S10 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S10 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Changes in T-cell phenotype distribution from screening to surgery for CANOPY-N as A, a T-cell phenotype count and B, a fraction of the total phenotypes per arm/time point.
View article: Figure S9 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S9 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Distribution of T-cell subgroups in CANOPY-1 using A, dimension 1, total immune infiltration and B, dimension 2, balance between immune suppressive signatures and antitumor immunity.
View article: Figure 1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure 1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
(A) PFS and (B) OS by CD8 IHC (low and high by median cutoff); (C) PFS and (D) OS by CD8 phenotype; and (E) PFS and (F) OS by T-cell–inflamed gene signature (low and high by median cutoff) in CANOP…
View article: Data from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Data from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Preclinical studies have shown that interleukin (IL)-1β blockade can modulate the tumor microenvironment (TME) to activate antitumor immunity and, in combination with immune checkpoint inhibitors (ICIs), prevent cancer growth. Our study in…
View article: Figure S4 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S4 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Cell phenotypes assessed by QIF: A, CD11b/CD66b stained for polymorphonuclear granulocytes (or neutrophils); B, CD163 stained for monocyte-lineage macrophages (or tumor-associated macrophages); and C, FOXP3/CD3 stained for regulatory T cel…
View article: Figure S7 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S7 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
A, CD8 central tumor levels by PD-L1 subgroups and B, summary of patient characteristics at baseline by PD-L1 subgroup for CANOPY-1.
View article: Figure S5 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S5 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Comparison of CD8 subgroups (median cut-off) with T-cell phenotypes for CANOPY-1, by A, CD8 level and B, T-cell phenotype.
View article: Table 1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Table 1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Baseline characteristics for CANOPY-1 and CANOPY-N population subsets
View article: Figure 2 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure 2 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
(A) PFS and (B) OS by treatment in CD8 low; (C) PFS and (D) OS by treatment in CD8 high for CANOPY-1. CT, chemotherapy.
View article: Figure S8 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S8 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Principal component analysis to deconvolve independent TME features in CANOPY-1. Dimension 1 indicates total immune infiltration and dimension 2 indicates the balance between immune supressive signatures and antitumor immunity.
View article: Figure S5 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S5 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Comparison of CD8 subgroups (median cut-off) with T-cell phenotypes for CANOPY-1, by A, CD8 level and B, T-cell phenotype.
View article: Figure S6 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S6 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
A, PFS and B, OS by low T-cell–inflamed signature and C, PFS and D, OS by high T-cell–inflamed signature for CANOPY-1.
View article: Figure S3 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S3 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
A, Classification of T-cell phenotypes based on CD8 IHC. In samples with paired RNA-Seq data, B, T-cell–inflamed gene signature and C, fibroblast gene signatures, by T-cell phenotype.
View article: Figure 6 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure 6 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
(A) Total CD8+ T cells, (B) intratumoral CD8+ T cells, (C) CD163+ TAMs, (D) CD66b+CD11b+ myeloid cells, (E) and FOXP3+ regulatory T cells …
View article: Figure 5 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure 5 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Relative gene signatures by CD8 subgroup in CANOPY-1. A, Heatmap showing enrichment of the TME gene signatures in the CD8 subgroups. B, MDSC-like macrophage and TAM gene signatures by T-cell phenotype and (C) and in hi…
View article: Figure S1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
A, CANOPY-1 and B, CANOPY-N study designs.
View article: Figure S3 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S3 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
A, Classification of T-cell phenotypes based on CD8 IHC. In samples with paired RNA-Seq data, B, T-cell–inflamed gene signature and C, fibroblast gene signatures, by T-cell phenotype.
View article: Figure 3 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure 3 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
(A) PFS and (B) OS by treatment in CD8+ desert tumors; (C) PFS and (D) OS by treatment in CD8+ excluded tumors; and (E) PFS and (F) OS by treatment in CD8+-inflamed…
View article: Figure S8 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S8 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Principal component analysis to deconvolve independent TME features in CANOPY-1. Dimension 1 indicates total immune infiltration and dimension 2 indicates the balance between immune supressive signatures and antitumor immunity.
View article: Supplementary Data tables from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Supplementary Data tables from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Tables S1 - S4
View article: Figure S4 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S4 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Cell phenotypes assessed by QIF: A, CD11b/CD66b stained for polymorphonuclear granulocytes (or neutrophils); B, CD163 stained for monocyte-lineage macrophages (or tumor-associated macrophages); and C, FOXP3/CD3 stained for regulatory T cel…
View article: Figure S2 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S2 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
T-cell phenotypes derived from VisioPharm IA software algorithm were established under pathology review using panCK (purple) as the tumor marked-up area. Semi-automatic scoring of CD8 (brown) in panCK-negative tumor stroma and panCK-positi…
View article: Figure S10 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S10 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Changes in T-cell phenotype distribution from screening to surgery for CANOPY-N as A, a T-cell phenotype count and B, a fraction of the total phenotypes per arm/time point.
View article: Figure S7 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S7 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
A, CD8 central tumor levels by PD-L1 subgroups and B, summary of patient characteristics at baseline by PD-L1 subgroup for CANOPY-1.
View article: Figure S11 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S11 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Distribution of viable tumor cells in CANOPY-N surgery samples in A, all patients, B, the CD8-low subgroup, and C, the CD8-high subgroup.
View article: Figure S2 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S2 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
T-cell phenotypes derived from VisioPharm IA software algorithm were established under pathology review using panCK (purple) as the tumor marked-up area. Semi-automatic scoring of CD8 (brown) in panCK-negative tumor stroma and panCK-positi…
View article: Supplementary Data tables from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Supplementary Data tables from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Tables S1 - S4